Find Pranlukast Hydrate manufacturers, exporters & distributors on PharmaCompass

Pranlukast Hydrate

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

18 API Suppliers, 17 JDMF, 1 EU WC, 10 KDMF, 5 Listed Suppliers, $ API Reference Price

18 API Suppliers
17 JDMF
1 EU WC
10 KDMF
5 Listed Suppliers
$ API Reference Price

INTERMEDIATES

12 Intermediates Suppliers

12 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

1 FDF Dossiers, 1 Listed Dossiers

1 FDF Dossiers
1 Listed Dossiers

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow

media
1 DATA COMPILATION #PharmaFlow

GLOBAL SALES INFORMATION

8 Annual Reports

globalSalesInformation
8 Annual Reports

MARKET PLACE

3 APIs

marketPlace
3 APIs

REF. STANDARDS & IMPURITIES

1 JP

otherSolutions
1 JP

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

API

FDF

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

298

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 103177-37-3, Azlaire, Ono-1078, Pranlukast hydrate, Ono 1078, Sb 205312

Molecular Formula

C₂₇H₂₃N₅O₄

Molecular Weight

481.5 g/mol

InChI Key

NBQKINXMPLXUET-UHFFFAOYSA-N

FDA UNII

TB8Z891092

Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.

1 2D Structure

Pranlukast Hydrate

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-[4-oxo-2-(2H-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide

2.1.2 InChI

InChI=1S/C27H23N5O4/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32)

2.1.3 InChI Key

NBQKINXMPLXUET-UHFFFAOYSA-N

2.1.4 Canonical SMILES

C1=CC=C(C=C1)CCCCOC2=CC=C(C=C2)C(=O)NC3=CC=CC4=C3OC(=CC4=O)C5=NNN=N5

2.2 Other Identifiers

2.2.1 UNII

TB8Z891092

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 8-(4 (4-phenylbutoxy)benzoyl)amino-2-(tetrazol-5'-yl)-4-oxo-4h-1-benzopyran

2. Ono 1078

3. Ono-1078

4. Ono-rs 411

5. Ono-rs-411

6. Sb 205312

2.3.2 Depositor-Supplied Synonyms

1. 103177-37-3

2. Azlaire

3. Ono-1078

4. Pranlukast Hydrate

5. Ono 1078

6. Sb 205312

7. Ccn 00401

8. Rs 411

9. Pranlukast (inn)

10. N-[4-oxo-2-(2h-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide

11. Onon

12. Ono-rs-411

13. 4-oxo-8-(4-(4-phenylbutoxy)benzoylamino)-2-(tetrazol-5-yl)-4h-1-benzopyran

14. Chembl21333

15. N-(4-oxo-2-(1h-tetrazol-5-yl)-4h-chromen-8-yl)-4-(4-phenylbutoxy)benzamide

16. Ccn-00401

17. Rs-411

18. Tb8z891092

19. Ncgc00181765-01

20. Sb-205312

21. Pranlukast [inn]

22. N-(4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl)-p-(4-phenylbutoxy)benzamide

23. N-(4-oxo-2-(2h-tetrazol-5-yl)-4h-chromen-8-yl)-4-(4-phenylbutoxy)benzamide

24. 8-[4(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4h-1-benzopyran;8-[4(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4h-1-benzopyran

25. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl]-p-(4-phenylbutoxy)benzamide;n-[4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl]-p-(4-phenylbutoxy)benzamide

26. Azlaire (tn)

27. Pranlukast [inn:ban]

28. Sr-05000001474

29. Unii-tb8z891092

30. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-chromen-8-yl]-4-(4-phenylbutoxy)benzamide

31. N-[4-oxo-2-(2h-tetrazol-5-yl)-1-benzopyran-8-yl]-4-(4-phenylbutoxy)benzamide

32. Pranlukast [mi]

33. Pranlukast [mart.]

34. Schembl3693

35. Dsstox_cid_23782

36. Dsstox_rid_80074

37. Pranlukast [who-dd]

38. Dsstox_gsid_43782

39. Mls006010078

40. Gtpl3634

41. Ono Rs-411

42. Dtxsid3043782

43. Schembl18058592

44. Chebi:94810

45. Hms2089h16

46. Hms3650a14

47. Hms3714e03

48. Bcp04577

49. Hy-b0290

50. Zinc1542146

51. Tox21_112952

52. Ac-696

53. Bdbm50023198

54. Mfcd00864631

55. Akos015967342

56. Ccg-220661

57. Db01411

58. Sb19080

59. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl]-4-(4-phenylbutoxy)benzamide

60. As-15105

61. Smr004701229

62. Cas-103177-37-3

63. Ft-0652673

64. P2115

65. C71133

66. D08408

67. Ab01275471-01

68. 177p373

69. L013134

70. Q7238392

71. Sr-05000001474-1

72. Sr-05000001474-2

73. Sr-05000001474-3

74. Brd-k97045029-001-01-9

75. Brd-k97045029-001-04-3

76. 8-[4-(4-phenylbutyloxy)benzoyl]amino-2-(tetrazol-5-yl)-4-oxo-4h-1-benzopyran

77. Benzamide, N-(4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl)-4-(4-phenylbutoxy)-

78. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl]-4(4-phenylbutoxy)benzamide

79. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-chromen-8-yl]-4-(4-phenyl-butoxy)-benzamide

80. Benzamide, N-(4-oxo-2-(2h-tetrazol-5-yl)-4h-1-benzopyran-8-yl)-4-(4-phenylbutoxy)-

81. Knt

82. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-chromen-8-yl]-4-(4-phenyl-butoxy)-benzamide (ono-rs-411)

83. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-chromen-8-yl]-4-(4-phenyl-butoxy)-benzamide(ono-rs-411)

2.4 Create Date

2005-03-25

3 Chemical and Physical Properties

Molecular Formula	C₂₇H₂₃N₅O₄
Molecular Weight	481.5 g/mol
XLogP3	4.2
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	9
Exact Mass	481.17500423 g/mol
Monoisotopic Mass	481.17500423 g/mol
Topological Polar Surface Area	119 Å²
Heavy Atom Count	36
Formal Charge	0
Complexity	778
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists.

5 Pharmacology and Biochemistry

5.1 Pharmacology

Pranlukast is a cysteinyl leukotriene receptor-1 antagonist.

5.2 MeSH Pharmacological Classification

Leukotriene Antagonists

A class of drugs designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level. (See all compounds classified as Leukotriene Antagonists.)

Anti-Asthmatic Agents

Drugs that are used to treat asthma. (See all compounds classified as Anti-Asthmatic Agents.)

5.3 ATC Code

R - Respiratory system

R03 - Drugs for obstructive airway diseases

R03D - Other systemic drugs for obstructive airway diseases

R03DC - Leukotriene receptor antagonists

R03DC02 - Pranlukast

5.4 Metabolism/Metabolites

Hepatic

5.5 Mechanism of Action

Pranlukast selectively antagonizes leukotriene D₄ (LTD₄) at the cysteinyl leukotriene receptor, CysLT₁, in the human airway. Pranlukast inhibits the actions of LTD₄ at the CysLT₁ receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.